Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Cited by 1,432
Related Papers
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron
|RePEc: Research Papers in Economics|0|647
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor
|Nature Communications|2014|400
Pathogenicity, transmissibility, and fitness of SARS-CoV-2 Omicron in Syrian hamsters
|Science|2022|222
A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses
|Nature Communications|2017|151